**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 50539**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma**

Wang Q *et al.* Hepatocellular carcinoma diagnosis

Qiang Wang, Qi Chen, Xia Zhang, Xiao-Lan Lu, Qin Du, Tao Zhu, Guo-Yuan Zhang, Dong-Sheng Wang, Qu-Ming Fan

**Qiang Wang, Xiao-Lan Lu, Qin Du, Guo-Yuan Zhang, Dong-Sheng Wang, Qu-Ming Fan,** Department of Laboratory Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China

**Qiang Wang,** Faculty of Laboratory Medicine, Center for Translational Medicine, North Sichuan Medical College, Nanchong 637000, Sichuan Province, China

**Qi Chen,** Department of Laboratory Medicine, Affiliated Sichuan Ba-Yi Rehabilitation Center of Chengdu University of TCM, Chengdu 610000, Sichuan Province, China

**Xia Zhang,** Department of Laboratory Medicine of the Ninth People’s Hospital of Chongqing, Chongqing 400700, China

**Tao Zhu**, Department of Preventive Medicine, North Sichuan Medical College, Nanchong 637000, Sichuan Province, China

**ORCID number:** Qiang Wang (0000-0001-9283-7729); Qi Chen (0000-0003-4991-8499); Xia Zhang (0000-0002-9594-9985); Xiao-Lan Lu (0000-0001-6273-4403); Qin Du (0000-0002-2933-0228); Tao Zhu (0000-0003-3344-8592); Guo-Yuan Zhang (0000-0003-1368-7633); Dong-Sheng Wang (0000-0003-1192-8798); Qu-Ming Fan (0000-0003-3342-1648).

**Author contributions:** All authors contributed to the conceptualisation and design of the study; Wang Q, Chen Q, and Zhang X contributed to the clinical data collection and analysis, and prepared and wrote the first draft of this manuscript; Lu XL, Du Q, and Zhang GY contributed to the clinical data collection; Zhu T contributed to the statistical analysis; Wang DS and Fan QM designed this study and revised the manuscript.

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the Affiliated Hospital of North Sichuan Medical College.

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agree to treatment by written consent.

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Data sharing statement:** No additional data are available.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Qu-Ming Fan,** **PhD, Research Assistant Professor,** Department of Laboratory Medicine, Affiliated Hospital of North Sichuan Medical College, 63 Wenhua Road, Nanchong 637000, Sichuan Province, China. fanqum@163.com

**Telephone:** +86-817-2190089

**Fax:** +86-817-2222856

**Received:** July 25, 2019

**Peer-review started:** July 25, 2019

**First decision:** August 17, 2019

**Revised:** August 25, 2019

**Accepted:** September 9, 2019

**Article in press:** September 9, 2019

**Published online:** September 28,2019

**Abstract**

***BACKGROUND***

Researchers have investigated the diagnostic value of protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), and obtained abundant clinical diagnostic data. However, PIVKA-II and AFP have unsatisfactory specificity and sensitivity in the diagnosis of early-stage HBV-related HCC. Gamma-glutamyltransferase (γ-GT) and aspartate aminotransferase (AST) are common biomarkers for evaluating liver function, and we hypothesized that the γ-GT/AST ratio in combination with PIVKA-II and AFP would improve the diagnosis of early-stage HBV-related HCC.

***AIM***

To evaluate the diagnostic value of γ-GT/AST ratio alone or in combination with PIVKA-II and AFP in HBV-related HCC.

***METHODS***

Serum levels of γ-GT, AST, PIVKA-II, and AFP were detected and analysed in 176 patients with HBV-related HCC and in 359 patients with chronic hepatitis B. According to tumour size and serum level of HBV DNA, HBV-related HCC patients were divided into the following categories: early-stage HCC patients, HCC patients, HBV DNA positive (HBV DNA+) HCC patients, and HBV DNA negative (HBV DNA-) HCC patients. Receiver-operating characteristic (ROC) curves were used to analyse and compare the diagnostic value of the single and combined detection of various biomarkers in different types of HBV-related HCC.

***RESULTS***

Tumour size was positively correlated with serum levels of PIVKA-II and AFP in HCC patients (*r* = 0.529, a*P* < 0.001and *r* = 0.270,b*P* < 0.001, respectively), but there was no correlation between tumour size and the γ-GT/AST ratio (*r* = 0.073, *P* = 0.336). The areas under the receiver-operating characteristic curves (AUROCs) of the γ-GT/AST ratio in early-stage HCC patients, HBV DNA+ HCC patients and HBV DNA- HCC patients were not significantly different from that in the total HCC patients (0.754, 0.802, and 0.705 *vs* 0.779, respectively; *P* > 0.05). When PIVKA-II was combined with the γ-GT/AST ratio in the diagnosis of early-stage HCC, HCC, and HBV DNA+ HCC, the AUROCs of PIVKA-II increased, with values of 0.857 *vs* 0.835, 0.925 *vs* 0.913, and 0.958 *vs* 0.954, respectively. When AFP was combined with the γ-GT/AST ratio in the diagnosis of early-stage HCC, HCC, HBV DNA+ HCC, and HBV DNA- HCC, the AUROCs of AFP increased, with values of 0.757 *vs* 0.621, 0.837 *vs* 0.744, 0.868 *vs* 0.757, and 0.840 *vs* 0.828, respectively.

***CONCLUSION***

The **γ-GT/AST ratio may be better than PIVKA-II and AFP in** the diagnosis of early-stage HBV-related **HCC**, and its **combination with** PIVKA-II and AFP **can improve the diagnostic value for** HBV-related **HCC.**

**Key words:** Gamma-glutamyltransferase; Aspartate aminotransferase; Protein induced by vitamin K absence or antagonist II; Alpha-fetoprotein; Hepatitis B virus; Hepatocellular carcinoma

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This study showed that the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST ratio) was not correlated with tumour size in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), and there was no difference in the AUROC between early-stage HBV-related HCC and HBV-related HCC, indicating that the γ-GT/AST ratio may be more useful than protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP) in the diagnosis of early-stage HBV-related HCC. PIVKA-II and AFP combined with the γ-GT/AST ratio can enhance the diagnostic value of these biomarkers in different categories of HBV-related HCC.

Wang Q, Chen Q, Zhang X, Lu XL, Du Q, Zhu T, Zhang GY, Wang DS, Fan QM. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma. *World J Gastroenterol* 2019; 25(36): 5515-5529

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i36/5515.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i36. 5515

**INTRODUCTION**

Hepatitis B virus (HBV) infection is the most common viral infection worldwide. It is estimated that more than 2 billion people worldwide have been infected with HBV, and more than 350 million people have developed chronic hepatitis B (CHB)[1]. HBV infection is associated with an increased risk of end-stage liver disease, cirrhosis, and hepatocellular carcinoma (HCC)[2-4]. Prospective population-based studies have shown that 15% of females and 20%-40% of males who are infected with HBV in the early stages of life will develop HCC[5]. It is estimated that approximately 300000 to 500000 people worldwide die from HCC every year[6,7]. In China, HCC is the 4th most common cancer and the 3rd leading cause of cancer death[8], and approximately 50% of the new cases of HCC each year worldwide occur in China[9].

Protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP) are widely used biomarkers in HCC diagnosis[10-13], and have been written into the guidelines for HCC diagnosis published by the National Society of Hepatology of different countries[14-16]. During clinical use, the sensitivity of AFP in the diagnosis of HCC is only 40%-60%, and the sensitivity of AFP in the diagnosis of early-stage HCC is only 10%-20%[17,18]. PIVKA-II is a kind of prothrombin that does not use vitamin K in the process of hepatocyte synthesis, leading to a synthesis deficiency. When HCC occurs due to the abnormal synthesis of prothrombin precursors by cancer cells, prothrombin precursor carboxylation is insufficient, resulting in a large amount of PIVKA-II[19]. As a newly discovered tumour marker for the diagnosis of HCC, PIVKA-II has higher diagnostic value than AFP[20,21]. Some studies have shown that PIVKA-II has a sensitivity of more than 90% in HCC diagnosis, while its sensitivity for early-stage HBV-related HCC detection is more than 50%[12,22,23]. When PIVKA-II and AFP are combined in HCC and early-stage HCC diagnosis, the diagnostic value is significantly improved compared to that of the detection of either individual protein[23-26].

Gamma-glutamyltransferase (γ-GT) is a membrane-binding enzyme that regulates the metabolism of glutathione, catalyses the degradation of extracellular glutathione, and then promotes the recovery of amino acids for intracellular glutathione synthesis. γ-GT has been recognized as being capable of enhancing the cellular antioxidant defence[27]. The level of γ-GT is abnormally elevated in patients with HCC. However, in other liver diseases, such as viral hepatitis, alcoholic hepatitis, and cirrhosis, the level of γ-GT is also abnormally elevated[28-32]. Therefore, for a long time, γ-GT could not be used as an effective index to diagnose HCC, and its specificity is only approximately 30%[33]. Aspartate aminotransferase (AST) is a biomarker commonly used to evaluate hepatocyte damage. The level of AST is elevated in acute and chronic viral hepatitis, alcoholic hepatitis, and cirrhosis. In HCC patients, AST is not elevated or is only slightly elevated[34,35]. Based on these observations, we believe that the ratio of γ-GT to AST (γ-GT/AST ratio) may be able to differentiate HCC from other liver diseases, aiding in the diagnosis and evaluation of HCC. At the same time, we also wanted to know whether the combination of the γ-GT/AST ratio and PIVKA-II or AFP, which are recognized biomarkers for the diagnosis of HCC, can improve the diagnostic value of PIVKA-II or AFP for HCC.

**MATERIALS AND METHODS**

***Study setting and patients***

A total of 535 patients with CHB, including 176 HCC patients and 359 CHB patients with other liver diseases, were retrospectively enrolled at the Affiliated Hospital of Northern Sichuan Medical College from January 2017 to March 2019. Among the 176 HCC patients, 74 early-stage HCC patients, 88 HBV DNA+ HCC patients, and 88 HBV DNA- HCC patients were included. The diagnosis of HCC was made in accordance with the standards of the guidelines for the diagnosis and treatment of primary HCC issued by the Chinese Society of Clinical Oncology (2018.V1). Early-stage HCC was defined as the presence of only a single tumour in the liver that was ≤ 5.0 cm, with no vascular invasion or extrahepatic metastasis[13,14]. A total of 359 CHB patients, including 186 with cirrhosis, 53 with cholecystitis, 37 with bile duct stones, 21 with drug-induced hepatitis, 51 with alcoholic hepatitis, 8 with hepatitis E infection, and 3 with hepatitis C infection, were included (258 HBV DNA+ patients and 101 HBV DNA- patients). The diagnosis of CHB and cirrhosis was in accordance with the revised guidelines for the prevention and treatment of CHB infection from the Chinese Society of Hepatology[36].

The study protocol was approved by the Ethics Committee of the Affiliated Hospital of North Sichuan Medical College, Nanchong, China.

***Measurements of γ-GT, AST, PIVKA-II, AFP, and HBV DNA***

Serum levels of γ-GT and AST were determined by biochemical rate-assay (AU5800, Beckman Coulter, Inc., America). Serum levels of PIVKA-II were determined by chemiluminescent microparticle immunoassay (CMIA) (Architect i1000, Abbott Laboratories, America). Serum levels of AFP were measured by electrochemiluminescence immunoassay (Cobas E602, Roche, Inc., Germany). Serum levels of HBV DNA were determined by real-time polymerase chain reaction (LightCycler 480II, Roche, Inc., Germany). The results were interpreted as follows: HBV DNA ≥ 500 IU/mL, positive (HBV DNA+); and HBV DNA ˂ 500 IU/mL, negative (HBV DNA-).

***Data processing for combined evaluation of γ-GT/AST ratio, PIVKA-II, and AFP***

The receiver-operating characteristic (ROC) curves were used to determine the diagnostic cut-off values of the γ-GT/AST ratio, PIVKA-II, and AFP for HCC. The fold change in the γ-GT/AST ratio, PIVKA-II, and AFP relative to the corresponding diagnostic cut-off values are expressed by the Mcut-off. This study evaluated the diagnostic value of the combined detection of biomarkers in HBV-related HCC by analysing the sums of the Mcut-off of the corresponding biomarkers.

***Statistical analysis***

Data are expressed as the median (interquartile range) or number (%). Comparisons between groups were performed by the Mann-Whitney *U* test. Pearson’s chi-square test was used for gender comparisons. Pearson correlation analysis was used for two-factor correlation analysis. ROC curves were used to determine the diagnostic cut-off values, the areas under the ROC curves (AUROCs), diagnostic sensitivities, and specificities. Statistical analyses were performed using SPSS, version 19.0 (SPSS Inc., United States) and Medcalc, version 12.3 (MedCalc Software bvba, Ostend, Belgium). The statistical significance of all tests was defined as *P* < 0.05 by two-tailed tests.

**RESULTS**

***Comparison of clinical characteristics between HCC group and chronic hepatitis B group***

The clinical characteristics of 176 patients with HCC and 359 patients with CHB (control group) are expressed as medians (interquartile range) or numbers (%). The data showed that the sex of the patients in the two groups was predominately male, and the median age of HCC patients was 53 (range, 47-62) years old, which was higher than that of the CHB group [49 (39-59) years] (*P* < 0.001). Serum levels of PIVKA-II, AFP, γ-GT, and γ-GT /AST ratio in HCC patients were significantly higher than those in CHB patients (*P* < 0.001), while serum levels of AST were significantly lower in HCC patients than in CHB patients (*P* < 0.001). The clinical characteristics of the 535 study patients are shown in Table 1.

***Diagnostic value of γ-GT/AST ratio, PIVKA-II, and AFP in early-stage HCC and*** ***HCC patients***

Tumour size was positively correlated with serum levels of PIVKA-II and AFP in HCC patients (*r* = 0.529, a*P* < 0.001 and *r* = 0.270, b*P* < 0.001, respectively), but there was no correlation between tumour size and the γ-GT/AST ratio (*r* = 0.073, *P* = 0.336) (Figure 1). Serum levels of PIVKA-II and AFP in early-stage HCC patients were significantly lower than those in advanced HCC patients (*P* < 0.001) and were higher than those in CHB patients (*P* < 0.001). The γ-GT/AST ratio was not significantly different between early-stage HCC patients and advanced HCC patients (*P* = 0.156), but higher than that in CHB patients (*P* < 0.001) (Figure 1).

When the cut-off values of the γ-GT/AST ratio, PIVKA-II, and AFP were set as 0.845, 84.44 mAu/mL, and 145.65 ng/mL, respectively, for the diagnosis of early-stage HCC, the AUROC of the γ-GT/AST ratio was 0.754 [95% confidence interval (CI): 0.700-0.809], which was lower than that of PIVKA-II [0.835 (95%CI: 0.776-0.893)] (*P* = 0.048) and was higher than that of AFP [0.621 (95%CI: 0.545-0.698)] (*P* = 0.006) (Figure 2A). When the cut-off values of the γ-GT/AST ratio, PIVKA-II, and AFP were set as 0.845, 162.22 mAu/mL, and 145.65 ng/mL, respectively, for HCC diagnosis, there was no difference in the AUROC between the γ-GT/AST ratio [0.779 (95%CI: 0.0.740-0.819)] and AFP [0.744 (95%CI: 0.695-0.792)] (*P* = 0.162), but the AUROCs of both γ-GT/AST and AFP were significantly lower than that of PIVKA-II [0.913 (95%CI: 0.884-0.943)] (*P* < 0.001) (Figure 2C). The AUROCs of PIVKA-II and AFP for the diagnosis of early-stage HCC were significantly lower than those for the diagnosis of HCC (c*P* = 0.020 and d*P* = 0.008, respectively), but there was no significant difference in the γ-GT/AST ratio between early-stage HCC and HCC (*P* = 0.468).

When combined with AFP for the diagnosis of early-stage HCC and HCC, the AUROCs of PIVKA-II decreased, with values of 0.798 (95%CI: 0.735-0.861) *vs* 0.835 (95%CI: 0.776-0.893) and 0.884 (95%CI: 0.850-0.919) *vs* 0.913 (95%CI: 0.884-0.943), respectively. When combined with the γ-GT/AST ratio for the diagnosis of early-stage HCC and HCC, the AUROCs of PIVKA-II increased, with values of 0.857 (95%CI: 0.807-0.906) *vs* 0.835 (95%CI: 0.776-0.893) and 0.925 (95%CI: 0.900-0.949) *vs* 0.913 (95%CI: 0.884-0.943), respectively. When combined with the γ-GT/AST ratio for the diagnosis of early-stage HCC and HCC, the AUROCs of AFP increased, with values of 0.757 (95%CI: 0.696-0.817) *vs* 0.621 (95%CI: 0.545-0.698) and 0.837 (95%CI: 0.801-0.873) *vs* 0.744 (95%CI: 0.695-0.792), respectively. When PIVKA-II was combined with the γ-GT/AST ratio and AFP for the diagnosis of early-stage HCC and HCC, there was almost no difference between the combined and single diagnostic abilities, with values of 0.834 (95%CI: 0.778-0.890) *vs* 0.835 (95%CI: 0.776-0.893) and 0.911 (95%CI: 0.884-0.939) *vs* 0.913 (95%CI: 0.884-0.943) (Figure 2B and 2D). The diagnostic performance of PIVKA-II, AFP, and the γ-GT/AST ratio for early-stage HCC and HCC is shown in Table 2.

***Diagnostic value of γ-GT/AST ratio, PIVKA-II, and AFP in HBV DNA+ and HBV DNA- HCC patients***

The mean tumour size of HBV DNA+ HCC patients was 7.40 (range, 4.10-10.38) cm, which was larger than that of HBV DNA- HCC patients [4.25 (2.00-8.80) cm] (*P* = 0.001). Serum levels of PIVKA-II and AFP in HBV DNA+ HCC patients were significantly higher than those in HBV DNA- HCC patients (a*P* = 0.003 and b*P* = 0.038, respectively), although there was no significant difference in the γ-GT/AST ratio between the two groups (*P* = 0.858). Serum levels of AFP and γ-GT/AST in HBV DNA+ CHB patients were significantly higher than those of HBV DNA- CHB patients (*P* < 0.001), but there was no significant difference in the levels of PIVKA-II between the two groups (*P* = 0.238). Serum levels of PIVKA-II, AFP, and γ-GT/AST had no correlation with serum levels of HBV DNA in HBV DNA+ HCC patients (c*P* = 0.377, d*P* = 0.799, and e*P* = 0.154, respectively) (Figure 3).

When the cut-off values of the γ-GT/AST ratio, PIVKA-II, and AFP were set as 0.640, 84.44 mAu/mL, and 497.70 ng/mL, respectively, for HBV DNA+ HCC patients, there was no significant difference in the AUROC between the γ-GT/AST ratio [0.802 (95%CI: 0.751-0.854)] and AFP [0.757 (95%CI: 0.689-0.825)] (*P* = 0.302), but the AUROCs of both γ-GT/AST and AFP were significantly lower than that of PIVKA-II [0.954 (95%CI: 0.923-0.985)] (*P* < 0.001) (Figure 4). When the cut-off value of the γ-GT/AST ratio, PIVKA-II, and AFP were set as 0.830, 154.92 mAu/mL, and 146.15 ng/mL, respectively, for the diagnosis of HBV DNA- HCC, the AUROCs of PIVKA-II and AFP were 0.861 (95%CI: 0.806-0.916) and 0.828 (95%CI: 0.768-0.888), respectively, and both of these AUROC values were significantly higher than that of the γ-GT/AST ratio [0.705 (95%CI: 0.632-0.779)] (f*P* < 0.001 and g*P* = 0.012, respectively), although there was no significant difference between the AUROCs of PIVKA-II and AFP (*P* = 0.430) (Figure 5). Compared with HBV DNA+ HCC patients, the AUROCs of PIVKA-II and the γ-GT/AST ratio decreased and the AUROC of AFP increased in HBV DNA- HCC patients.

When PIVKA-II was combined with AFP and the γ-GT/AST ratio in both HBV DNA+ and HBV DNA- HCC patients, there were no significant differences in the AUROCs between combined diagnosis and single diagnosis (AFP: h*P* = 0.791 and i*P* = 0.583; γ-GT/AST: j*P* = 0.851 and i*P* = 0.959). The AUROC of AFP combined with the γ-GT/AST ratio in the diagnosis of HBV DNA+ HCC patients was 0.868 (95%CI: 0.824-0.913), which was higher than that of AFP (*P* = 0.008). The highest AUROC for the combined diagnosis of HBV DNA- HCC was 0.884 (95%CI: 0.837-0.932), but there was no significant difference between this AUROC and the AUROC of PIVKA-II (*P* = 0.533) (Figure 5). The diagnostic performance of PIVKA-II, AFP, and the γ-GT/AST ratio for HBV DNA + and HBV DNA- HCC patients is shown in Table 3.

**DISCUSSION**

This study assessed the diagnostic value of the γ-GT/AST ratio, PIVKA-II, and AFP in HBV-related early-stage HCC patients, HBV DNA+ HCC patients, HBV DNA- HCC patients, and HCC patients. It was found that PIVKA-II was superior to the γ-GT/AST ratio and AFP in the diagnosis of the above mentioned categories of HCC, and the γ-GT/AST ratio was superior to AFP in the diagnosis of early-stage HCC, HBV DNA+ HCC, and HCC. AFP was superior for the diagnosis of HBV DNA- HCC compared to the diagnosis of early-stage HCC, HBV DNA+ HCC, and HCC. The γ-GT/AST ratio may be superior to PIVKA-II and AFP for the detection of early-stage HCC. At the same time, the combination of PIVKA-II and/or AFP with the γ-GT/AST ratio can improve the diagnostic value of these biomarkers for early-stage HCC, DNA+ HCC, HBV DNA- HCC, and HCC.

According to the statistical analysis of HCC at our hospital over the past five years, the proportion of HCC patients infected with HBV was 88.28% (610/691), indicating that HBV was the main cause of HCC in China. The HCC patients and control patients who were chosen for this study had suffered from HBV infection for more than 6 mo, and it was very important to evaluate the serum levels of PIVKA-II, AFP, and γ-GT/AST and their diagnostic value in this subset of HCC patients.

In this study, we evaluated the diagnostic value of the combined detection of PIVKA-II, AFP, and the γ-GT/AST ratio in HCC by analysing the Mcut-off results, which were mainly based on the following two considerations: First, in the diagnosis of cancer, a higher serum level of tumour markers indicates a higher risk that patients are suffering from tumours; second, the positivity of a single tumour marker does not necessarily indicate that the probability of cancer is high. However, the simultaneous positive expression of multiple tumour markers, even at low titres, should be taken seriously. Therefore, the use of the Mcut-off to evaluate the diagnostic value of PIVKA-II, AFP, and the γ-GT/AST ratio can effectively improve the diagnosis of HCC, and the data in this study also confirmed the hypothesis stated above.

γ-GT is considered a biomarker of alcoholic hepatitis[29-32], and the γ-GT/AST ratio has been used to differentiate the types of jaundice[37]. The data in this paper showed that serum level of γ-GT increased in CHB patients, but the level was lower than that in HCC patients. Additionally, serum level of AST also increased in CHB patients and was higher than that in HCC patients (Table 1). Therefore, the ratio of γ-GT and AST could help to differentiate HCC and CHB patients and to perform a differential diagnosis. At the same time, the statistical analysis also confirmed our previous assumptions.

When PIVKA-II, AFP, and the γ-GT/AST ratio were individually used for the diagnosis of early-stage HCC, HBV DNA+ HCC, HBV DNA- HCC, and HCC, the diagnostic value of PIVKA-II was significantly higher than that of AFP and the γ-GT/AST ratio, especially in regard to the diagnostic sensitivity, which is consistent with the view of Yu R; additionally, PIVKA-II was superior to AFP in the diagnosis of early-stage HCC[13]. However, we should also note that PIVKA-II and AFP were significantly positively correlated with the tumour size in HCC (Figure 1A and 1B), which is an important reason why PIVKA-II and AFP had significantly lower diagnostic value in early-stage HCC than in HCC (AUROC: 0.839 *vs* 0.914 and 0.628 *vs* 0.744, respectively). The γ-GT/AST ratio was not correlated with the tumour size in HCC (Figure 1C), and there was no difference in the AUROC between early-stage HCC and HCC (AUROC: 0.755 *vs* 0.779). Therefore, we inferred that the γ-GT/AST ratio may be more useful than PIVKA-II and AFP in the diagnosis of early-stage HCC. It may be that intrahepatic obstruction in HCC induces hepatocytes to produce abundant γ-GT, while cancer cells also synthesize γ-GT, making the serum level of γ-GT elevated higher than that of benign liver disease, while AST was elevated lower than that of benign liver disease. Thus, the γ-GT/AST ratio is conducive to early-stage HCC diagnosis. This observation will be validated in our follow-up study. Serum levels of AFP in HBV DNA+ HCC patients and HBV DNA+ CHB patients were significantly higher than those in HBV DNA- HCC patients and HBV DNA- CHB patients, respectively, indicating that HBV replication may promote the expression of AFP in abnormal hepatocytes. It is more of a stretch to assume that the continuous replication of HBV causes HCC in CHB patients. This observation may be the main reason that the cut-off value of AFP in HBV DNA+ HCC patients was significantly higher than that in HBV DNA- HCC patients (497.70 ng/mL *vs* 146.15 ng/mL). Additionally, AFP had the largest AUROC in HBV DNA- HCC patients, even though the tumour size of HBV DNA- HCC patients was smaller than that of HBV DNA+ HCC patients; thus, AFP has the greatest diagnostic ability for HBV DNA- HCC. Serum levels of PIVKA-II in HBV DNA+ HCC patients were higher than those in HBV DNA- HCC patients, but there was no significant difference between HBV DNA+ CHB patients and HBV DNA- CHB patients, which indicated that the reason for the decrease in the AUROC of PIVKA-II in HBV DNA- HCC have been that the tumour size of HBV DNA- HCC was significantly smaller than that of HBV DNA+ HCC. A higher AUROC value indicates that there is greater diagnostic value[38]. When PIVKA-II and AFP were combined with the γ-GT/AST ratio in the diagnosis of early-stage HCC, HBV DNA+ HCC, and HBV DNA- HCC, the AUROCs of PIVKA-II and AFP increased, and the increase for AFP was especially larger. Therefore, PIVKA-II and AFP combined with the γ-GT/AST ratio will be more useful for the differential diagnosis of HCC and other benign liver diseases than these biomarkers individually.

In conclusion, the γ-GT/AST ratio may be more useful than PIVKA-II and AFP in the diagnosis of early-stage HCC, and AFP has the greatest diagnostic ability for HBV DNA- HCC. PIVKA-II and AFP combined with the γ-GT/AST ratio can increase the diagnostic value of these biomarkers in different types of HCC. Therefore, clinicians need to select the most advantageous biomarkers for HCC according to clinical and laboratory test results.

**Article Highlights**

***Research background***

Protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP) are widely used biomarkers in the diagnosis of hepatocellular carcinoma (HCC), and have been written into the guidelines for HCC diagnosis published by the National Society of Hepatology of different countries. However, PIVKA-II and AFP have unsatisfactory specificity and sensitivity in the diagnosis of hepatitis B virus (HBV)-related HCC, especially in early-stage HBV-related HCC.

***Research motivation***

Researchers have evaluated the diagnostic value of biomarkers in HCC. However, it is difficult to obtain ideal biomarkers for early-stage HCC, even if combined detection of existing biomarkers. This study evaluated the diagnostic value of the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST ratio) in different classifications of HBV-related HCC, which can effectively improve the diagnostic efficiency for HBV-related HCC.

***Research objectives***

The objective of this study was to evaluate the diagnostic value of the γ-GT/AST ratio, PIVKA-II, and AFP, alone or in combination, in different categories of HBV-related HCC.

***Research methods***

We retrospectively analyzed the clinical and laboratory data of HBV-related HCC and chronic hepatitis B (CHB) patients, and classified those data according to the tumour size and serum level of HBV DNA. The diagnostic value of the γ-GT/AST ratio, PIVKA-II, and AFP in different categories of HBV-related HCC was evaluated comprehensively and systematically.

***Research results***

Tumour size was positively correlated with serum levels of PIVKA-II and AFP in HCC patients, but there was no correlation between tumour size and the γ-GT/AST ratio. The areas under receiver-operating characteristic curves (AUROCs) of the γ-GT/AST ratio were not significantly different between early-stage HBV-related HCC patients and HBV-related HCC patients. When PIVKA-II and AFP were combined with the γ-GT/AST ratio in the diagnosis of HBV-related HCC patients, early-stage HBV-related HCC patients, HBV DNA+ HCC patients, and HBV DNA- HCC patients, the AUROCs of those biomarkers were increased.

***Research conclusions***

The **γ-GT/AST ratio is a useful biomarker for the diagnosis of** HBV-related **HCC and may be more useful than PIVKA-II and AFP in** the diagnosis of early-stage HBV-related **HCC**. T**he combination of** PIVKA-II and AFP **with the γ-GT/AST ratio can enhance the diagnostic value of these biomarkers in** different categories of HBV-related **HCC.**

***Research perspectives***

This study assessed the diagnostic value of the γ-GT/AST ratio, PIVKA-II, and AFP in different categories of HBV-related **HCC. According to the correlation between tumour size of** HBV-related **HCC patients and** the γ-GT/AST ratio, we inferred that the γ-GT/AST ratio may be more useful than PIVKA-II and AFP in the diagnosis of early-stage HCC. This hypothesis should be validated in future studies.**REFERENCES**

1 **Lavanchy D**. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat* 2004; **11**: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]

2 **Lee WM**. Hepatitis B virus infection. *N Engl J Med* 1997; **337**: 1733-1745 [PMID: 9392700 DOI: 10.1056/NEJM199712113372406]

3 **Kanda T**, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. *Int J Mol Sci* 2019; **20**: [PMID: 30889843 DOI: 10.3390/ijms20061358]

4 **Sarin SK**, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int* 2016; **10**: 1-98 [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4]

5 **McMahon BJ**, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. *Ann Intern Med* 2001; **135**: 759-768 [PMID: 11694101 DOI: 10.7326/0003-4819-135-9-200111060-00006]

6 **Lozano R**, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**: 2095-2128 [PMID: 23245604 DOI: 10.1016/S0140-6736(12)61728-0]

7 **Parkin DM**, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. *Int J Cancer* 2001; **94**: 153-156 [PMID: 11668491 DOI: 10.1002/ijc.1440]

8 **Chen W**, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016; **66**: 115-132 [PMID: 26808342 DOI: 10.3322/caac.21338]

9 **Torre LA**, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; **65**: 87-108 [PMID: 25651787 DOI: 10.3322/caac.21262]

10 **Jun T**, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, Yu ML, Tanaka Y, Nguyen MH. Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. *Hepatol Commun* 2019; **3**: 493-503 [PMID: 30976740 DOI: 10.1002/hep4.1321]

11 **Kim SH**, Moon DB, Kim WJ, Kang WH, Kwon JH, Jwa EK, Cho HD, Ha SM, Chung YK, Lee SG. Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation. *Hepatobiliary Surg Nutr* 2016; **5**: 461-469 [PMID: 28124000 DOI: 10.21037/hbsn.2016.11.05]

12 **Wang X**, Zhang W, Liu Y, Gong W, Sun P, Kong X, Yang M, Wang Z. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. *Infect Agent Cancer* 2017; **12**: 47 [PMID: 28852419 DOI: 10.1186/s13027-017-0153-6]

13 **Yu R**, Tan Z, Xiang X, Dan Y, Deng G. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. *BMC Cancer* 2017; **17**: 608 [PMID: 28863782 DOI: 10.1186/s12885-017-3609-6]

14 **Chinese Society of Clinical Oncology.** Guidelines of Chinese Society of Clinical Oncology (CSCO) Hepatocellular Carcinoma. 1th ed. People's Medical Publishing House, 2018: 3-21

15 **Kudo M**, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. *Dig Dis* 2011; **29**: 339-364 [PMID: 21829027 DOI: 10.1159/000327577]

16 **Izumi N**. Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline. *Oncology* 2010; **78** Suppl 1: 78-86 [PMID: 20616588 DOI: 10.1159/000315234]

17 **Gao J**, Song P. Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China: Expectation. *Drug Discov Ther* 2017; **11**: 168-169 [PMID: 28757516 DOI: 10.5582/ddt.2017.01036]

18 **Ertle JM**, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, Gerken G, Schlaak JF. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma. *Digestion* 2013; **87**: 121-131 [PMID: 23406785 DOI: 10.1159/000346080]

19 **Zhang YS**, Chu JH, Cui SX, Song ZY, Qu XJ. Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma. *Cell Physiol Biochem* 2014; **34**: 903-915 [PMID: 25200250 DOI: 10.1159/000366308]

20 **Hirokawa F**, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y, Uchiyama K. Outcomes and predictors of microvascular invasion of solitary hepatocellular carcinoma. *Hepatol Res* 2014; **44**: 846-853 [PMID: 23834279 DOI: 10.1111/hepr.12196]

21 **Poté N**, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. *J Hepatol* 2015; **62**: 848-854 [PMID: 25450201 DOI: 10.1016/j.jhep.2014.11.005]

22 **Svobodova S**, Karlikova M, Topolcan O, Pecen L, Pestova M, Kott O, Treska V, Slouka D, Kucera R. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study. *In Vivo* 2018; **32**: 1551-1554 [PMID: 30348715 DOI: 10.21873/invivo.11413]

23 **Wu J**, Xiang Z, Bai L, He L, Tan L, Hu M, Ren Y. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. *Cancer Biomark* 2018; **23**: 235-242 [PMID: 30103302 DOI: 10.3233/CBM-181402]

24 **Yoshida M**, Ogino H, Iwata H, Hattori Y, Hashimoto S, Nakajima K, Sasaki S, Hara M, Sekido Y, Mizoe JE, Shibamoto Y. Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma. *Oncol Lett* 2019; **17**: 3026-3034 [PMID: 30854081 DOI: 10.3892/ol.2019.9922]

25 **Seo SI**, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, Jang MK, Lee JH, Kim JS, Kim HY, Kim DJ, Lee MS, Park CK. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. *World J Gastroenterol* 2015; **21**: 3928-3935 [PMID: 25852278 DOI: 10.3748/wjg.v21.i13.3928]

26 **Hemken PM**, Sokoll LJ, Yang X, Dai J, Elliott D, Gawel SH, Lucht M, Feng Z, Marrero JA, Srivastava S, Chan DW, Davis GJ. Validation of a novel model for the early detection of hepatocellular carcinoma. *Clin Proteomics* 2019; **16**: 2 [PMID: 30675135 DOI: 10.1186/s12014-018-9222-0]

27 **Whitfield JB**. Gamma glutamyl transferase. *Crit Rev Clin Lab Sci* 2001; **38**: 263-355 [PMID: 11563810 DOI: 10.1080/20014091084227]

28 **Tsutsumi M**, Sakamuro D, Takada A, Zang SC, Furukawa T, Taniguchi N. Detection of a unique gamma-glutamyl transpeptidase messenger RNA species closely related to the development of hepatocellular carcinoma in humans: a new candidate for early diagnosis of hepatocellular carcinoma. *Hepatology* 1996; **23**: 1093-1097 [PMID: 8621139 DOI: 10.1002/hep.510230524]

29 **Goldberg DM**, Martin JV. Role of gamma-glutamyl transpeptidase activity in the diagnosis of hepatobiliary disease. *Digestion* 1975; **12**: 232-246 [PMID: 241676 DOI: 10.1159/000197682]

30 **Braun JP**, Bardies J, Thouvenot JP, Benard P, Rico AG. Serum gamma-glutamyltransferase in equids: reference physiologic values. *Am J Vet Res* 1982; **43**: 339-340 [PMID: 6124195]

31 **Ruppin DC**, Frydman MI, Lunzer MR. Value of serum gamma-glutamyltransferase activity in the diagnosis of hepatobiliary disease. *Med J Aust* 1982; **1**: 421-424 [PMID: 6124872]

32 **Xia J**, Song P, Sun Z, Sawakami T, Jia M, Wang Z. Advances of diagnostic and mechanistic studies of γ-glutamyl transpeptidase in hepatocellular carcinoma. *Drug Discov Ther* 2016; **10**: 181-187 [PMID: 27534452 DOI: 10.5582/ddt.2016.01052]

33 **Faber W**, Sharafi S, Stockmann M, Denecke T, Sinn B, Puhl G, Bahra M, Malinowski MB, Neuhaus P, Seehofer D. Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. *Surgery* 2013; **153**: 510-517 [PMID: 23122930 DOI: 10.1016/j.surg.2012.09.015]

34 **Dufour DR**, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. *Clin Chem* 2000; **46**: 2050-2068 [PMID: 11106350]

35 **Park SJ**, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Bang HI. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. *Medicine (Baltimore)* 2017; **96**: e5811 [PMID: 28296720 DOI: 10.1097/MD.0000000000005811]

36 **Chinese Society of Hepatology and Chinese Society of Infectious Diseases,** **Chinese Medical Association.** The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. *Zhongguo Ganzangbing Zazhi* 2015; 7: 1–18 [DOI: 10.3969/j.issn.1674-7380.2015.03.001]

37 **Tamarkina AD**, Dement'eva ES, Krylova NI. [Enzyme diagnosis of mechanical jaundice]. *Vopr Med Khim* 1985; **31**: 101-104 [PMID: 4090351]

38 **Cook NR**. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. *Clin Chem* 2008; **54**: 17-23 [PMID: 18024533 DOI: 10.1373/clinchem.2007.096529]

**P-Reviewer:** Kai K, Pompella A

**S-Editor:** Tang JZ **L-Editor:** Wang TQ **E-Editor:** Zhang YL

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Characteristics of the study population (*n* = 535)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **CHB (*n* = 359)** | **HCC (*n* = 176)** | ***P*-value** |
| Age (yr) | 49 (39-59) | 53 (47-62) | <0.001 |
| Gender (male: female) | 281:78 | 152:24 | 0.025 |
| PIVKA-II (mAU/mL) | 22.88 (16.00-37.70) | 4882.77 (274.98-30000) | <0.001 |
| AFP (ng/mL) | 31.00 (5.30-126.00) | 510.05 (25.91-9583.93) | <0.001 |
| γ-GT (U/L) | 92.00 (47.50-160.70) | 151.55 (68.10-346.20) | <0.001 |
| AST (U/L) | 138.40 (56.00-367.00) | 76.25 (44.25-131.75) | <0.001 |
| γ-GT/AST | 0.58 (0.26-1.22) | 1.84 (0.95-3.38) | <0.001 |
| HBV DNA+, *n* (%) | 258 (71.87%) | 88 (50.00%) | NA |
| Early-stage HCC, *n* (%) | NA | 74 (42.05%) | NA |

Data are expressed as the median (interquartile range) or number (%). CHB: Chronic hepatitis B; HCC: Hepatocellular carcinoma; PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT: Gamma-glutamyltransferase; AST: Aspartate aminotransferase; NA: Not applicable.

**Table 2 Performance of protein induced by vitamin K absence or antagonist II, alpha-fetoprotein, and the ratio of gamma-glutamyltransferase to aspartate aminotransferase in early-stage hepatocellular carcinoma and hepatocellular carcinoma**


|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Early-stage HCC** | | | | | **HCC** | | | | |
| **Cut-off** | **SEN (%)** | **SPE (%)** | **PPV (%)** | **NPV (%)** | **Cut-off** | **SEN (%)** | **SPE (%)** | **PPV (%)** | **NPV (%)** |
| PIVKA-II (mAu/mL) | | 84.44 | 68.90 | 89.70 | 57.96 | 93.33 | 162.22 | 81.30 | 93.60 | 86.16 | 91.08 |
| AFP (ng/mL) | 145.65 | 47.30 | 77.20 | 29.95 | 87.66 | 145.65 | 64.80 | 77.20 | 58.22 | 81.73 |
| γ-GT/AST | 0.845 | 78.40 | 64.90 | 31.53 | 93.58 | 0.845 | 81.80 | 64.90 | 53.33 | 87.91 |
| PIVKA-II + AFP | NA | 60.80 | 90.80 | 57.67 | 91.83 | NA | 73.30 | 93.90 | 85.49 | 87.77 |
| PIVKA-II + γ-GT/AST | NA | 74.30 | 86.60 | 53.34 | 94.24 | NA | 86.90 | 83.80 | 72.45 | 92.88 |
| AFP + γ-GT/AST | NA | 56.80 | 81.90 | 39.28 | 90.19 | NA | 76.10 | 76.30 | 61.15 | 86.69 |
| PIVKA-II + AFP + γ-GT/AST | NA | 73.00 | 82.50 | 46.23 | 93.68 | NA | 78.40 | 91.10 | 81.20 | 89.59 |

HCC: Hepatocellular carcinoma; SEN: Sensitivity; SPE: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; NA: Not applicable.


**Table 3 Performance of protein induced by vitamin K absence or antagonist** II**, alpha-fetoprotein, and the ratio of gamma-glutamyltransferase and aspartate aminotransferase in hepatitis B virus DNA+ and hepatitis B virus DNA- hepatocellular carcinoma patients**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **HBV DNA+ HCC** | | | | | **HBV DNA- HCC** | | | | |
| **Cut-off** | **SEN (%)** | **SPE (%)** | **PPV (%)** | **NPV (%)** | **Cut-off** | **SEN (%)** | **SPE (%)** | **PPV (%)** | **NPV (%)** |
| PIVKA-II (mAu/mL) | 84.44 | 92.00 | 92.60 | 80.92 | 97.14 | 154.92 | 72.70 | 91.10 | 87.68 | 79.30 |
| AFP (ng/mL) | 497.70 | 58.00 | 88.80 | 63.85 | 86.11 | 146.15 | 58.00 | 97.00 | 94.40 | 72.61 |
| γ-GT/AST | 0.640 | 88.60 | 60.50 | 43.34 | 93.96 | 0.830 | 85.20 | 52.50 | 60.98 | 80.28 |
| PIVKA-II + AFP | NA | 89.80 | 92.20 | 79.70 | 96.36 | NA | 80.70 | 87.10 | 84.50 | 83.82 |
| PIVKA-II + γ-GT/AST | NA | 89.80 | 92.60 | 80.54 | 96.38 | NA | 79.50 | 78.20 | 76.06 | 81.41 |
| AFP + γ-GT/AST | NA | 70.50 | 89.10 | 68.81 | 89.85 | NA | 75.00 | 78.20 | 74.98 | 78.21 |
| PIVKA-II + AFP + γ-GT/AST | NA | 90.90 | 92.20 | 79.90 | 96.74 | NA | 79.50 | 86.10 | 83.29 | 82.82 |


HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; SEN: Sensitivity; SPE: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; NA: Not applicable.




**Figure 1 Analysis of gamma-glutamyltransferase to aspartate aminotransferase ratio.** A-C: Correlations of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), and the ratio of gamma-glutamyltransferase and aspartate aminotransferase (γ-GT/AST) with tumour size; D-F: Comparison of serum levels of PIVKA-II, AFP, and γ-GT/AST between early-stage hepatocellular carcinoma (HCC) patients, advanced HCC patients, and chronic hepatitis B patients.PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B.




**Figure 2 Receiver-operating characteristic curves of protein induced by vitamin K absence or antagonist II, alpha-fetoprotein, the ratio of gamma-glutamyltransferase to aspartate aminotransferase, and their combinations in hepatocellular carcinoma patients.** A and B: Receiver-operating characteristic (ROC) curves of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST), and their combinations in early-stage hepatocellular carcinoma (HCC) patients; chronic hepatitis B patients (CHB) served as controls; C and D: ROC curves of PIVKA-II, AFP, γ-GT/AST, and their combinations in HCC patients; CHB patients served as controls.ROC curve: Receiver-operating characteristic curve; PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B.



**Figure 3 Correlations of serum levels of protein induced by vitamin K absence or antagonist** II**, alpha-fetoprotein, and the ratio of gamma-glutamyltransferase to aspartate aminotransferase with hepatitis B virus DNA.** A-C: Comparisons of serum levels of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), and the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST) between hepatitis B virus (HBV) DNA+ and HBV DNA- hepatocellular carcinoma (HCC) patients; D-F: Comparisons of serum levels of PIVKA-II, AFP, and γ-GT/AST between HBV DNA+ and HBV DNA- chronic hepatitis B patients. G-I: Correlations of PIVKA-II, AFP, and γ-GT/AST with serum levels of HBV DNA in HBV DNA+ HCC patients. PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B.



**Figure 4 Diagnostic value of protein induced by vitamin K absence or antagonist** II**, alpha-fetoprotein, and the ratio of gamma-glutamyltransferase to aspartate aminotransferase in hepatitis B virus DNA+ hepatocellular carcinoma patients.** A-C: Comparisons of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), and the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST) between hepatitis B virus (HBV) DNA+ hepatocellular carcinoma (HCC) patients and HBV DNA+ chronic hepatitis B (CHB) patients; D: Receiver-operating characteristic (ROC) curves of PIVKA-II, AFP, and γ-GT/AST in HBV DNA+ HCC patients; HBV DNA+ CHB patients served as controls; E: ROC curves of the combinations of PIVKA-II, AFP, and γ-GT/AST in HBV DNA+ HCC patients; HBV DNA+ CHB patients served as controls. PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B; ROC curve: Receiver-operating characteristic curve.



**Figure 5 Diagnostic value of protein induced by vitamin K absence or antagonist** II**, alpha-fetoprotein, and the ratio of gamma-glutamyltransferase to aspartate aminotransferase in hepatitis B virus DNA- hepatocellular carcinoma patients.** A-C: Comparisons of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP) ,and the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST) between hepatitis B virus (HBV) DNA- hepatocellular carcinoma (HCC) patients and HBV DNA- chronic hepatitis B (CHB) patients; D: Receiver-operating characteristic (ROC) curves of PIVKA-II, AFP, and γ-GT/AST in HBV DNA- HCC patients; HBV DNA- CHB patients served as controls; E: ROC curves of the combinations of PIVKA-II, AFP, and γ-GT/AST in HBV DNA- HCC patients; HBV DNA- CHB patients served as controls.PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B; ROC curve: Receiver-operating characteristic curve.